Blood-Based Biomarkers for Neurological Disorders
Neurological disorders are among the most pressing challenges in medicine, and advances in proteomics now enable detection of central nervous system pathology through blood to support earlier detection, longitudinal tracking, and population-scale research.
In this white paper, explore how next-generation technologies – SomaScan™ Assay, KREX™ and CyTOF™ – are being used to interrogate the proteome, immunoproteome and immune cells in blood. Through real-world case studies across Alzheimer’s disease, autism, schizophrenia and more, see how these tools are revealing disease-specific signatures. Gain insights into integrating these approaches into your workflow and explore what’s next for clinical adoption of BBBs.
White paper highlights:
- Understand how BBBs provide a scalable alternative to CSF for neurological research
- Explore case studies using protein, autoantibody and single-cell profiling to identify BBBs across neurological disorders
- Learn how to integrate SomaScan, KREX and CyTOF platforms into your biomarker discovery workflow
- Gain perspective on the future of BBBs and key challenges to clinical adoption